ALK and non-small cell lung carcinoma: Besides, pemetrexed was shown to be superior to docetaxel in both ORR (29% vs. 7%, respectively) and PFS (4.2 months vs. 2.6 months, respectively) for ALK-rearrangement NSCLC patients progressing on platinum-based chemotherapy [5].